Terns Pharmaceuticals, Inc. (TERN) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 10 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for TERN is $55.67, representing a +5.7% upside from the current price of $52.68. Price targets range from a low of $35.00 to a high of $70.00.
